Paul Mattels

Stock Analyst at Stifel

(n/a)

# 4,714

Out of 4,820 analysts

4

Total ratings

n/a

Success rate

-35.99%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Paul Mattels

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	DNLI Denali Therapeutics	Upgrades: Buy	$37	$16.17	+128.82%	3	Dec 16, 2024
	ALEC Alector	Initiates: Buy	$44	$1.16	+3,693.10%	1	Feb 19, 2020

Denali Therapeutics

Dec 16, 2024

Upgrades: Buy

Price Target: $37

Current: $16.17

Upside: +128.82%

Alector

Feb 19, 2020

Initiates: Buy

Price Target: $44

Current: $1.16

Upside: +3,693.10%